Bio-TechneMEX:TECH 83 PS Ratio is 7.72 as of Jul. 02, 2026, which is 26% below its 10-year median of 10.37. GuruFocus rates MEX:TECH with a GF Score™ of 83/100 and a GF Value™ of MXN1,113.50. The stock has 8 warning signs investors should review. Among 933 Biotechnology companies, Bio-Techne ranks better than 50.8% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Bio-Techne's share price is MXN1090.00.
Bio-Techne's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was MXN141.27. Hence, Bio-Techne's PS Ratio for today is 7.72.
Warning Sign:
Bio-Techne Corp stock PS Ratio (=9.2) is close to 1-year high of 9.2.
The historical rank and industry rank for Bio-Techne's PS Ratio or its related term are showing as below:
MEX:TECH'
s PS Ratio Range Over the Past 10 Years
Min: 5.61 Med: 10.37 Max: 23.45
Current: 9.2
During the past 13 years, Bio-Techne's highest PS Ratio was 23.45. The lowest was 5.61. And the median was 10.37.
MEX:TECH's PS Ratio is ranked better than 50.8% of 933
companies
in the Biotechnology industry
Industry Median: 9.53
vs MEX:TECH: 9.20
Bio-Techne's Revenue per Sharefor the
three
months ended in Mar. 2026 was MXN35.68.
Its Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was MXN141.27.
Warning Sign:
Bio-Techne Corp revenue growth has slowed down over the past 12 months.
During the past 12 months, the average Revenue per Share Growth Rate of Bio-Techne was 2.30% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 4.30% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 9.50% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 10.20% per year.
During the past 13 years, Bio-Techne's highest 3-Year average Revenue per Share Growth Rate was 23.00% per year. The lowest was 4.30% per year. And the median was 12.45% per year.
Back to Basics: PS Ratio
Bio-Techne (MEX:TECH) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Bio-Techne PS Ratio Related Terms
Bio-Techne PS Ratio Historical Data
* Premium members only.
The historical data trend for Bio-Techne's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Bio-Techne's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bio-Techne PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Bio-Techne's PS Ratio distribution charts can be found below:
* The bar in red indicates where Bio-Techne's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Bio-Techne's Share Price of today is MXN1090.00. Bio-Techne's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN141.27.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Bio-Techne (MEX:TECH) has a PS Ratio of 7.72 as of Jul. 02, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Bio-Techne and its competitors. This is 26% below median its historical median of 10.37. Over the past decade, Bio-Techne's PS Ratio has ranged from 5.61 to 23.45. According to the industry distribution chart, Bio-Techne ranks #459 out of 933 companies in the Biotechnology industry, placing it in the top 49.2%.
Is Bio-Techne's PS Ratio too high?
Bio-Techne's current PS Ratio of 7.72 is 26% below median its 10-year median of 10.37. Over the past 10 years, this metric has ranged from a low of 5.61 to a high of 23.45. The Biotechnology industry median PS Ratio is 9.53. Bio-Techne's value of 7.72 is 19% below this industry median. Based on the distribution chart, Bio-Techne ranks #459 out of 933 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Bio-Techne has a GF Score™ of 83/100, reflecting its overall financial health beyond just this single metric.
How does Bio-Techne's PS Ratio compare to ARWR and CYTK?
According to the Biotechnology industry distribution chart, Bio-Techne ranks #459 out of 933 companies for PS Ratio. This puts Bio-Techne in the upper half of its industry. The industry median PS Ratio is 9.53. Bio-Techne's value of 7.72 is 19% below this benchmark. Historically, Bio-Techne's own PS Ratio has ranged from 5.61 to 23.45 over the past decade. While the company's 10-year median is 10.37 vs. the industry median of 9.53, Bio-Techne has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.53, based on 933 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bio-Techne's current PS Ratio of 7.72 is 19% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Bio-Techne and its competitors. For the Biotechnology industry, the median PS Ratio is 9.53 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bio-Techne's current PS Ratio is 7.72, which is 26% below median its own 10-year median of 10.37. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bio-Techne stock overvalued right now?
Bio-Techne (MEX:TECH) has a current PS Ratio of 7.72. The stock's GF Value™ is MXN1,113.50, compared to a current price of MXN1,090.00 — trading 2.1% below its estimated fair value. The current PS Ratio is 7.72, which is 26% below median its 10-year median of 10.37 and 19% below the Biotechnology industry median of 9.53. Bio-Techne's overall GF Score™ is 83/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Bio-Techne (MEX:TECH), the current PS Ratio is 7.72 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bio-Techne (MEX:TECH) Overvalued in 2026?
Based on GuruFocus' analysis, Bio-Techne stock appears to be undervalued.
The current stock price of MXN1,090.00 is trading 2.1% below its estimated GF Value™ of MXN1,113.50.
Key valuation signals for MEX:TECH:
PS Ratio: 7.72 (26% below median its 10-year median of 10.37)
GF Value™: MXN1,113.50 vs. price of MXN1,090.00 (2.1% below fair value)
Industry Position: 19% below the Biotechnology median (#459 of 933)
No single metric tells the full story. See the MEX:TECH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (about 75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.
83GF Score
Get the complete analysis for MEX:TECH
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:TECH has been successfully added to your 
